| Srl | Item |
| 1 |
ID:
085863
|
|
|
|
|
| Publication |
2008.
|
| Summary/Abstract |
The Agreement on Trade-Related Aspects of Intellectual Property Rights is the most important as well as the most controversial instrument to date concerning intellectual property protection. What is not clear is the impact it will have on developing countries and whether it will actually meet its objective in the "… promotion of technological innovation and to the transfer and dissemination of technology …". The proponents of a strong patent regime vehemently argue that strengthening patent protection will lead to greater technology transfer in developing countries, and consequently inflow of foreign direct investment (FDI) as it is the most important channel for technology transfer. This article takes the Indian pharmaceutical industry as an example to examine the above assertion, and argues that simply enhancing patent protection may not necessarily result in a corresponding increase in FDI in the Indian pharmaceutical sector. It shows that in addition to strong patent protection, there are equally or even more important factors that have a bearing on the inflow of FDI.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2 |
ID:
110293
|
|
|
|
|
| Publication |
2011.
|
| Summary/Abstract |
India's economic reforms since 1990s and World Trade Organisation's Agreement on Trade-Related Aspects of Intellectual Property Rights have caused significant changes in the operational environment of the Indian pharmaceutical industry (IPI). In this backdrop, this study examines the Foreign Direct Investment (FDI) flows into the firms of IPI. It finds that the amount of FDI, the number of FDI recipient firms and the number of source countries of FDI are larger during the product patent regime as compared to the process patent regime. The factor analysis of primary data presents the perception of 64 sample firms of IPI as regards the main constraints of FDI inflows in the product patent regime.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3 |
ID:
136258
|
|
|
|
|
| Summary/Abstract |
The paper analyzes the effect of India's membership in the World Trade Organization (WTO) and its signing of the TRIPs agreement on the pharmaceutical industry in general and the Indian sector in particular. First, it examines the effect of the implementation of the provisions of TRIPs on the growth of the national and multinational sectors of the industry. Second, it analyzes whether the new WTO rules will necessarily benefit pharmaceutical companies from the West, especially the United States and Switzerland, and whether there is evidence to support the assertion made by industry insiders that by 2015 multinational corporations will reestablish their monopoly of the industry by controlling at least 60% of the Indian market. Third, it investigates whether the multinational monopoly of the drug industry has had—or will have—a negative consequence for Indian consumers. Finally, the article examines the ways in which Indian companies are responding to the challenges of globalization and analyzes their new strategies, such as (1) outsourcing deals with multinationals to produce generic and patented drugs, (2) increasing R&D activities to enable them to make a transition from being drug “imitators” to drug “innovators,” (3) undertaking contract research, including outsourced clinical trials, (4) collaborating in joint R&D and product and process development to synergize their knowledge-base and effectively exploit available human resources and infrastructure (Ranbaxy's alliance with GlaxoSmithKline), and (5) undergoing a consolidation phase through indigenous mergers and acquisitions and strategic alliances.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|